These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
228 related articles for article (PubMed ID: 25689895)
1. Seminal fluid: a useful source of prostate cancer biomarkers? Roberts MJ; Richards RS; Gardiner RA; Selth LA Biomark Med; 2015; 9(2):77-80. PubMed ID: 25689895 [No Abstract] [Full Text] [Related]
2. Diagnostic performance of expression of PCA3, Hepsin and miR biomarkers inejaculate in combination with serum PSA for the detection of prostate cancer. Roberts MJ; Chow CW; Schirra HJ; Richards R; Buck M; Selth LA; Doi SA; Samaratunga H; Perry-Keene J; Payton D; Yaxley J; Lavin MF; Gardiner RA Prostate; 2015 Apr; 75(5):539-49. PubMed ID: 25597828 [TBL] [Abstract][Full Text] [Related]
3. Multi-omics Biomarker Pipeline Reveals Elevated Levels of Protein-glutamine Gamma-glutamyltransferase 4 in Seminal Plasma of Prostate Cancer Patients. Drabovich AP; Saraon P; Drabovich M; Karakosta TD; Dimitromanolakis A; Hyndman ME; Jarvi K; Diamandis EP Mol Cell Proteomics; 2019 Sep; 18(9):1807-1823. PubMed ID: 31249104 [TBL] [Abstract][Full Text] [Related]
4. Seminal cell-free DNA molecular profile as a novel diagnostic and prognostic prostate cancer biomarkers. Ponti G; Maccaferri M; Manfredini M; Cotugno M; Pellacani G; Conti A; Micali S; Mandrioli M; Tomasi A Med Hypotheses; 2018 May; 114():69. PubMed ID: 29602469 [No Abstract] [Full Text] [Related]
5. C-type natriuretic peptide and its precursor: potential markers in human prostate cancer. Lippert S; Iversen P; Brasso K; Goetze JP Biomark Med; 2015; 9(4):319-26. PubMed ID: 25808436 [TBL] [Abstract][Full Text] [Related]
6. Presurgical Biomarker Performance in the Detection of Gleason Upgrading in Prostate Cancer. Wittig K; Yamzon JL; Smith DD; Jeske DR; Smith SS Cancer Epidemiol Biomarkers Prev; 2016 Dec; 25(12):1643-1645. PubMed ID: 27543619 [TBL] [Abstract][Full Text] [Related]
7. Clinical applications of molecular biomarkers in prostate cancer detection. Dumache R; Miclea F; Bumblăcilă B; Puiu M Rev Med Chir Soc Med Nat Iasi; 2010; 114(2):470-5. PubMed ID: 20700989 [TBL] [Abstract][Full Text] [Related]
8. Human seminal fluid as a source of prostate cancer-specific microRNA biomarkers. Selth LA; Roberts MJ; Chow CW; Marshall VR; Doi SA; Vincent AD; Butler LM; Lavin MF; Tilley WD; Gardiner RA Endocr Relat Cancer; 2014 Aug; 21(4):L17-21. PubMed ID: 24859988 [No Abstract] [Full Text] [Related]
9. [Clinical study on PAP, gamma-Sm and PA as tumor markers in prostatic cancer patients]. Ohashi T; Akagi T; Irie S; Obama T; Nasu Y; Tohjoh S; Takeda K; Yoshimoto J; Matsumura Y; Ohmori H Nihon Hinyokika Gakkai Zasshi; 1987 Aug; 78(8):1403-8. PubMed ID: 2449560 [No Abstract] [Full Text] [Related]
10. The role of the prostate cancer antigen 3 (PCA3) test for the diagnosis of prostate cancer in the era of opportunistic prostate-specific antigen screening. Ficarra V; Novara G; Zattoni F Eur Urol; 2010 Oct; 58(4):482-4; discussion 484-5. PubMed ID: 20685032 [No Abstract] [Full Text] [Related]
11. Detection of the Prostate Cancer Biomarker PCA3 with Electrochemical and Impedance-Based Biosensors. Soares JC; Soares AC; Rodrigues VC; Melendez ME; Santos AC; Faria EF; Reis RM; Carvalho AL; Oliveira ON ACS Appl Mater Interfaces; 2019 Dec; 11(50):46645-46650. PubMed ID: 31765118 [TBL] [Abstract][Full Text] [Related]
12. Going viral? Linking the etiology of human prostate cancer to the Teixeira AA; Marchiò S; Dias-Neto E; Nunes DN; da Silva IT; Chackerian B; Barry M; Lauer RC; Giordano RJ; Sidman RL; Wheeler CM; Cavenee WK; Pasqualini R; Arap W EMBO Mol Med; 2017 Oct; 9(10):1327-1330. PubMed ID: 28751581 [TBL] [Abstract][Full Text] [Related]
13. PSGR and PCA3 as biomarkers for the detection of prostate cancer in urine. Rigau M; Morote J; Mir MC; Ballesteros C; Ortega I; Sanchez A; Colás E; Garcia M; Ruiz A; Abal M; Planas J; Reventós J; Doll A Prostate; 2010 Dec; 70(16):1760-7. PubMed ID: 20672322 [TBL] [Abstract][Full Text] [Related]
14. PSA, PCA3 and the phi losophy of prostate cancer management. Melichar B Clin Chem Lab Med; 2013 Apr; 51(4):707-12. PubMed ID: 23518451 [No Abstract] [Full Text] [Related]
15. Growth inhibition properties of the putative prostate cancer biomarkers PSP94 and CRISP-3. Van Eynde A; Litovkin K; Bollen M Asian J Androl; 2011 Mar; 13(2):205-6. PubMed ID: 21102472 [No Abstract] [Full Text] [Related]
16. Contemporary role of prostate cancer gene 3 in the management of prostate cancer. Roobol MJ Curr Opin Urol; 2011 May; 21(3):225-9. PubMed ID: 21301341 [TBL] [Abstract][Full Text] [Related]
17. Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test. Roobol MJ; Schröder FH; van Leeuwen P; Wolters T; van den Bergh RC; van Leenders GJ; Hessels D Eur Urol; 2010 Oct; 58(4):475-81. PubMed ID: 20637539 [TBL] [Abstract][Full Text] [Related]
18. Diagnosis of prostate cancer by analyzing oxidative stress in human seminal plasma: developing unsophisticated tools for noninvasive prostate cancer diagnosis. Barrio-Muñoz M; Abad-Gairín C; Amengual-Guedán JM; Prats-López J Eur J Cancer Prev; 2016 Nov; 25(6):518-23. PubMed ID: 26633164 [TBL] [Abstract][Full Text] [Related]